Farmacologicamente discutendo

Romano Danesi Dipartimento di Oncologia ed Emato-Oncologia Università degli Studi di Milano

REVOLUTIONARY ROAD IN CLL

Innovazione rivoluzionaria nella terapia della leucemia linfatica cronica


Disclosures

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
MSD			Х		Х		
Eisai			Х		Х	Х	
AstraZeneca	Х		Х		Х	Х	
BeiGene					Х		
Janssen	Х		Х		Х		
Novartis			Х		Х		
Lilly			Х		Х		
Incyte			Х		Х		
AB Science			Х				
Sanofi			Х		Х	Х	
Abbvie			Х		Х		

REVOLUTIONARY ROAD IN CLL

Innovazione rivoluzionaria nella terapia della leucemia linfatica cronica

Relationship between drug exposure and effects (therapeutic and adverse)




Applied Pharmacokinetics, 3rd ed. Vancouver, WA: Applied Therapeutics; 1992. pp.1-3

REVOLUTIONARY ROAD IN CLL

Innovazione rivoluzionaria nella terapia della leucemia linfatica cronica



Relationship between drug exposure and effects (therapeutic and adverse)



Innovazione rivoluzionaria nella terapia della leucemia linfatica cronica

The rationale of venetoclax-ibrutinib combination

- Ibrutinib and venetoclax have distinct and complementary modes of action that work synergistically to eliminate distinct CLL cell populations.
- CLL cells rely on the overexpression of antiapoptotic proteins (BCL-2, BCL extralarge [XL], and myeloid cell leukemia-1 [MCL-1]) for survival.
- Ibrutinib decreases BCL-XL and MCL-1, but not BCL-2, in highly proliferative lymph node emigrant B cells (CD5hi CXCR4dim), mobilizes CLL cells from lymph nodes and lymphoid niches into the peripheral blood, and enhances their susceptibility to venetoclax-induced apoptosis.

Moreno C et al. Blood Advances 2023; 7:5294-5303

Padova, 22 maggio 2024 Hotel NH Padova

The rationale of venetoclax-ibrutinib combination

- Combined venetoclax plus ibrutinib demonstrated synergistic antitumor activity in preclinical CLL models, with greater cytotoxicity observed with the combination than with either agent alone.
- Additionally, recent clinical studies with venetoclax plus ibrutinib demonstrated high undetectable minimal residual disease rates in both peripheral blood and bone marrow in patients with CLL.


Tam CS et al. https://doi.org/10.1182/blood.2021014488



Padova, 22 maggio 2024 Hotel NH Padova

6

The distinct and complementary mechanisms of ibrutinib and venetoclax




Zhang et al. Biomarker Research (2022) 10:17



Padova, 22 maggio 2024 Hotel NH Padova

Ibrutinib plus venetoclax rapidly eradicates CLL cells (data from CAPTIVATE)




Padova, 22 maggio 2024 Hotel NH Padova

8

Innovazione rivoluzionaria nella terapia della leucemia linfatica cronica

Pre-treatment with ibrutinib increases CLL cell sensitivity to venetoclax



Deng J et al. Leukemia (2017) 31, 2075-2084




Padova, 22 maggio 2024 Hotel NH Padova

9

REVOLUTIONARY ROAD IN CLL

Innovazione rivoluzionaria nella terapia della leucemia linfatica cronica


BIM expression is increased in CLL cells treated in vivo with BTK inhibition



Deng J et al. Leukemia (2017) 31, 2075-2084

Padova, 22 maggio 2024 Hotel NH Padova

In vivo BTK inhibition increases BCL-2 dependence in cells from CLL patients




Deng J et al. Leukemia (2017) 31, 2075-2084



REVOLUTIONARY ROAD IN CLL

Innovazione rivoluzionaria nella terapia della leucemia linfatica cronica

Treatment-naive CLL cells are characterized by both high BCL-2 dependency and apoptotic priming




Rigo A et al. Cell Death and Disease (2024) 15:323



Padova, 22 maggio 2024 Hotel NH Padova

Rationale for ibrutinib combination with targeted agent venetoclax



Padova, 22 maggio 2024 Hotel NH Padova

REVOLUTIONARY ROADAN Ghal (2021) 11:79 Innovazione rivoluzionaria nella terapia della leucemia linfatica cronica

Conclusions

- The complementary effects of venetoclax and ibrutinib on CLL mitochondria strongly supports their exploration of these combinations in the clinic.
- The combination of venetoclax and ibrutinib is highly active and well-tolerated and provide fixed-duration options for patients with CLL.



Padova, 22 maggio 2024 Hotel NH Padova